Welcome to our dedicated page for Raysearch Laboratories Ab news (Ticker: RSLBF), a resource for investors and traders seeking the latest updates and insights on Raysearch Laboratories Ab stock.
The RAYSEARCH LABS AB ORD (RSLBF) news page on Stock Titan aggregates company announcements and media releases related to RaySearch Laboratories AB (publ), a medical technology company that develops oncology software for improved cancer treatment. RaySearch’s communications cover its treatment planning system RayStation, oncology information system RayCare, oncology analytics system RayIntelligence, and treatment control system RayCommand.
Investors and followers of RSLBF can use this news feed to review financial reporting updates, such as interim and year-end reports where RaySearch presents information on order intake, net sales, operating profit, and significant events. These reports are often accompanied by webcasts in which company representatives present developments and answer questions from analysts and investors.
The news stream also features product and technology updates. RaySearch issues releases on advancements in RayStation, RayCare, and RayIntelligence, including new functionalities in particle therapy treatment planning, adaptive radiation therapy, workflow automation, and oncology analytics. Announcements may highlight the adoption of RaySearch products by radiotherapy and proton therapy centers, collaborations with clinical partners, and participation in industry conferences such as the Particle Therapy Cooperative Group (PTCOG) meeting.
In addition, RaySearch publishes corporate governance and shareholder information, including bulletins from annual general meetings where board elections, remuneration guidelines, and auditor appointments are decided. These items provide insight into the company’s governance structure and decisions affecting shareholders.
By following the RSLBF news page, readers can monitor RaySearch’s financial disclosures, software developments in radiation therapy and oncology information systems, clinic adoptions and collaborations, and formal corporate decisions, all in one place.
RaySearch Laboratories has announced its upcoming Year-end report presentation for 2024, scheduled for February 21, 2025, at 10:00 am CET. The report will be released earlier the same day at 07:45 am CET and will be accessible on raysearchlabs.com along with presentation slides.
The presentation will be conducted via webcast, featuring Johan Löf, founder and CEO, and Nina Grönberg, CFO, who will discuss the company's development. The presentation will be held in English, followed by a Q&A session for attendees.
Interested parties, including analysts, investors, and media representatives, can access the presentation through the provided webcast link: RaySearch Q4, 2024.
RaySearch Laboratories is celebrating its tenth anniversary of innovation in proton therapy at the PTCOG 62 conference in Singapore, from June 10-15, 2024. The company will showcase advancements in RayStation, RayCare, and RayIntelligence systems.
Since delivering its first proton plan in 2014, RayStation has been adopted by 120 centers globally. RayStation introduces features like automated replanning, LET optimization, and FLASH planning. RayCare enhances oncology workflows, and RayIntelligence offers cloud-based analytics for better decision-making.
A user meeting and various presentations will be part of PTCOG 62, highlighting ongoing research and user testimonials.
RaySearch Laboratories has released its interim report for Q1 2024. The company showed strong financial performance with order intake reaching SEK 238.5 M, net sales of SEK 257.2 M, and an operating profit of SEK 45.8 M. Profit after tax was SEK 36.7 M, and earnings per share stood at SEK 1.07. Significant events included RayStation's implementation in over 1,000 radiotherapy centers and the acquisition of DrugLog. Post-reporting period highlights include a collaboration agreement with C-RAD and RayCare being certified for interoperability with Varian TrueBeam.
The Annual General Meeting 2021 of RaySearch Laboratories AB was held on May 26, 2021, via postal voting due to the pandemic. Key resolutions included the re-election of board members, approval of financial statements, and the adoption of remuneration guidelines for senior executives. Accumulated profits of SEK 202,699,000 will be balanced in new accounts. The meeting also confirmed Ernst & Young as the auditor and approved the board's remuneration report for 2020. Further information is available on raysearchlabs.com.